COMMENTS: Filling the gap between pharmaceutical grade cannabinoid
derivative production through RWE. FDA will need to tighten up it’s
response to CBD products with legal cannabis production booming in the US
at the state level. The Federal framework needs to catch up quickly.
IMPACT: High, fill gaps in research about the safety and efficacy of CBD
using RWD/RWE, Better Data for a Better Understanding of the Use and Safety
READ TIME: 4 mins
*1. “Washington State lawmakers on Thursday introduced landmark legislation
to decriminalize possessing small amounts of all drugs and expand treatment
services for people with substance use disorders, part of a growing trend
of U.S. states backing away from a crime-control model of drug enforcement
and instead treating the issue as a public health matter.” *
*2. “The proposal would eliminate criminal penalties for possession of
so-called “personal use amounts” of controlled substances and direct the
Washington State Health Care Authority (HCA) to craft a plan under which
“continual, rapid and widespread access to a comprehensive continuum of
care must be provided to all persons with substance use disorder.”” *
*3. “Alison Holcomb, the political director for ACLU of Washington and an
author of the state’s 2012 marijuana legalization initiative, told
Marijuana Moment the decriminalization measure continues the organization’s
overarching goal “to demonstrate that it’s possible to replace punitive
responses to drug use with a public health approach, and achieve better
outcomes for our communities.”” *
*4. “One noteworthy change from past versions of the proposal is that HB
1499 appears not to tap into state cannabis tax revenue in order to fund
expanded treatment services, as organizers previously indicated the bill
might do.” *
*5. “—. Marijuana Moment is already tracking more than 500 cannabis,
psychedelics and drug policy bills in state legislatures and Congress this
year.” *
Source URL:
FDA Unveils Plan To Fill CBD Research Gaps With ‘Real-World Data’ In 2021
Alternative URL:
https://www.fda.gov/news-events/fda-voices/better-data-better-understanding-use-and-safety-profile-cannabidiol-cbd-products